Wearable monitoring to collect health data in people receiving transfusions for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses an Axivity AX3 accelerometer worn by participants to collect continuous activity and movement data alongside regular quality-of-life questionnaires and routine blood tests. Adults with MDS, AML, myeloma or MPN/MDS who plan to receive disease-modifying treatment and transfusions are enrolled and monitored over the treatment period. The team will compare wearable-derived activity and symptom patterns with patient-reported outcomes and transfusion events to identify signals linked to fatigue, breathlessness and treatment tolerance. Participants with significant cardiac devices, severe comorbidity, poor performance status, or who are hospitalized are excluded, and all visits take place at Oxford University Hospitals NHS Trust.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS), myeloma and AML
* Intention to undertake disease modifying treatment
* Life expectancy ≥ 6 months
* Able to complete quality of life questionnaires
* Willing and able to provide informed consent for participation in the study
* Willing to receive blood products as part of normal NHS care

Exclusion Criteria:

* Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG ≥3)
* Participants with known arrhythmias or other significant cardiological conductivity disorders
* Patients with severe comorbidities
* Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety of the patient or quality of the data
* Hospitalised patients
* Patients currently participating in another interventional clinical study
* Patients with a pacemaker or implanted cardioverter defibrillator or any cardiac implanted device

Where it's running

• Oxford University Hospitals NHS Trust
  Oxford, Oxfordshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Matthew H Poynton, MBBS — University of Oxford
• Study coordinator: Matthew H Poynton, MBBS
• Email: matthew.poynton@linacre.ox.ac.uk
• Phone: +447742990230

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

  This study tests whether continuing ivosidenib after induction helps people with IDH1-mutated AML or high-risk MDS who can’t have a transplant, to see if it helps keep cancer from returning.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07607418

• Haplo-cord Blood Transplant for AML and high-risk MDS

  This study tests a haploidentical-cord blood stem cell transplant approach in patients with AML or high-risk MDS to see how different engraftment patterns affect outcomes.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian and 3 other locations · NCT07588360

• Treosulfan vs Melphalan conditioning before allogeneic transplant in AML/MDS

  In this study, adults with AML or MDS who are getting an allogeneic transplant try two different conditioning regimens (Treosulfan or Melphalan) to see which one works better and is easier to tolerate.

  Recruiting at 16 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT07025824

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults

  This trial tests CARCIK-CD123/33 cell therapy to see if it is safe and feasible for people with relapsed or refractory AML or BPDCN, including kids and adults, before planned stem cell transplant.

  Recruiting Phase 1/2 Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Monza, MB and 1 other locations · NCT07877610

• Soursop tea in relapsed/refractory AML or multiple myeloma

  This pilot study tests whether drinking tea made from soursop leaves can help reduce cancer cells in people with relapsed or refractory AML or MM.

  Recruiting Early Phase 1 Cooper Norcross Health · Camden, New Jersey · NCT07771803

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.